Neutropenia (Hematology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia – Drugs In Development, 2021, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neutropenia – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 1, 2, 6, 6, 11, 1 and 1 respectively.

Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).

– The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Apotex Inc

Aprilbio Co Ltd

BeyondSpring Inc

Biocon Ltd

Biocure Technology Inc

Biosidus SA

Biosimilar Solutions LLC

Cellerant Therapeutics Inc

Cleveland BioLabs Inc

CPL Biologicals Pvt Ltd

Dr. Reddy's Laboratories Ltd

EmendoBio Inc

Genova Biotech Company Ltd

Ilkogen Ilac San Ve Tic AS

Kaleido Biosciences Inc

Kashiv BioSciences LLC

Ligand Pharmaceuticals Inc

Lupin Ltd

Merck & Co Inc

Mycenax Biotech Inc

Nexgen Biosciences

Phoenicia Biosciences Inc

Prolong Pharmaceuticals LLC

Qilu Pharmaceutical Co Ltd

Richter Gedeon Nyrt

Shenzhen Xinpeng Bio-technology Co Ltd

Siam Bioscience Co Ltd

Tanvex BioPharma Inc

Toko Pharmaceutical Industries Co Ltd

USV Pvt Ltd

X4 Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Neutropenia - Overview

Neutropenia - Therapeutics Development

Neutropenia - Therapeutics Assessment

Neutropenia - Companies Involved in Therapeutics Development

Neutropenia - Drug Profiles

Neutropenia - Dormant Projects

Neutropenia - Discontinued Products

Neutropenia - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Neutropenia, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Neutropenia – Pipeline by Apotex Inc, 2021

Neutropenia – Pipeline by Aprilbio Co Ltd, 2021

Neutropenia – Pipeline by BeyondSpring Inc, 2021

Neutropenia – Pipeline by Biocon Ltd, 2021

Neutropenia – Pipeline by Biocure Technology Inc, 2021

Neutropenia – Pipeline by Biosidus SA, 2021

Neutropenia – Pipeline by Biosimilar Solutions LLC, 2021

Neutropenia – Pipeline by Cellerant Therapeutics Inc, 2021

Neutropenia – Pipeline by Cleveland BioLabs Inc, 2021

Neutropenia – Pipeline by CPL Biologicals Pvt Ltd, 2021

Neutropenia – Pipeline by Dr. Reddy's Laboratories Ltd, 2021

Neutropenia – Pipeline by EmendoBio Inc, 2021

Neutropenia – Pipeline by Genova Biotech Company Ltd, 2021

Neutropenia – Pipeline by Ilkogen Ilac San Ve Tic AS, 2021

Neutropenia – Pipeline by Kaleido Biosciences Inc, 2021

Neutropenia – Pipeline by Kashiv BioSciences LLC, 2021

Neutropenia – Pipeline by Ligand Pharmaceuticals Inc, 2021

Neutropenia – Pipeline by Lupin Ltd, 2021

Neutropenia – Pipeline by Merck & Co Inc, 2021

Neutropenia – Pipeline by Mycenax Biotech Inc, 2021

Neutropenia – Pipeline by Nexgen Biosciences, 2021

Neutropenia – Pipeline by Phoenicia Biosciences Inc, 2021

Neutropenia – Pipeline by Prolong Pharmaceuticals LLC, 2021

Neutropenia – Pipeline by Qilu Pharmaceutical Co Ltd, 2021

Neutropenia – Pipeline by Richter Gedeon Nyrt, 2021

Neutropenia – Pipeline by Shenzhen Xinpeng Bio-technology Co Ltd, 2021

Neutropenia – Pipeline by Siam Bioscience Co Ltd, 2021

Neutropenia – Pipeline by Tanvex BioPharma Inc, 2021

Neutropenia – Pipeline by Toko Pharmaceutical Industries Co Ltd, 2021

Neutropenia – Pipeline by USV Pvt Ltd, 2021

Neutropenia – Pipeline by X4 Pharmaceuticals Inc, 2021

Neutropenia – Dormant Projects, 2021

Neutropenia – Dormant Projects, 2021 (Contd..1)

Neutropenia – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Neutropenia, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports